Literature DB >> 12270768

Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors.

Fen-Pi Chou1, Shu-Chen Chu, Ming-Chun Cheng, Shun-Fa Yang, Wing-Nam Cheung, Hui-Ling Chiou, Yih-Shou Hsieh.   

Abstract

OBJECTIVES: Increased cell expression of matrix metalloproteinase-9 (MMP-9) was associated with the development of atherosclerosis and osseoarticular tissue destruction in hemodialysis patients. In this study, the pre- and post-HD plasma concentrations of type IV collagenases and their inhibitors in HD patients were examined. DESIGN AND METHODS: Commercial ELISA kits and Zymography techniques were used to assay the parameters in 40 patients pre- and post-HD session.
RESULTS: After the hemodialysis process, MMP-9, MMP-2 and TIMP-2 levels were 124 +/- 72, 706 +/- 242 and 248 +/- 90 ng/mL, significantly different from the pre-HD values (187 +/- 148, 759 +/- 304 and 43 +/- 14 ng/mL). TIMP-1 were not affected by HD. Female subjects and patients with chronic glomerulonephritis had higher TIMP-2 than their counterparts (p < 0.05). The effect of gender on MMP-2 levels was interacted with that of membrane types (p < 0.01).
CONCLUSION: These results indicated that the hemodialysis process tends to decrease the overall activity of the peripheral plasma MMP system in HD patients. Copyright 2002 The Canadian Society of Clinical Chemists

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270768     DOI: 10.1016/s0009-9120(02)00331-4

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

1.  Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.

Authors:  Li-Che Lu; Chung-Wei Yang; Wen-Yeh Hsieh; Wan-Hsuan Chuang; Yi-Chang Lin; Chih-Sheng Lin
Journal:  Clin Exp Nephrol       Date:  2015-12-28       Impact factor: 2.801

2.  Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis.

Authors:  Zhongxin Jiang; Tao Sui; Bin Wang
Journal:  Rheumatol Int       Date:  2009-09-25       Impact factor: 2.631

3.  Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.

Authors:  Jacek Rysz; Maciej Banach; Robert A Stolarek; Dimitri P Mikhailidis; Aleksandra Cialkowska-Rysz; Lech Pokoca; Mariusz Piechota; Zbigniew Baj
Journal:  Int Urol Nephrol       Date:  2009-12-02       Impact factor: 2.370

4.  Associations of markers of inflammation and coagulation with delirium during critical illness.

Authors:  Timothy D Girard; Lorraine B Ware; Gordon R Bernard; Pratik P Pandharipande; Jennifer L Thompson; Ayumi K Shintani; James C Jackson; Robert S Dittus; E Wesley Ely
Journal:  Intensive Care Med       Date:  2012-08-18       Impact factor: 17.440

5.  Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease.

Authors:  Ryan S Friese; Fangwen Rao; Srikrishna Khandrika; Brenda Thomas; Michael G Ziegler; Geert W Schmid-Schönbein; Daniel T O'Connor
Journal:  Clin Exp Hypertens       Date:  2009-10       Impact factor: 1.749

6.  Identification, purification and partial characterization of tissue inhibitor of matrix metalloproteinase-2 in bovine pulmonary artery smooth muscle.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Sajal Chakraborti
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

7.  The significance of altered gelatinase expression in the synovium of patient with arthritic effusions.

Authors:  Ko-Hsiu Lu; Shun-Fa Yang; Shu-Chen Chu; Pei-Ni Chen; Ming-Chih Chou; Tang-Yan Hsiao; Yih-Shou Hsieh
Journal:  Clin Rheumatol       Date:  2003-11-19       Impact factor: 2.980

Review 8.  Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review.

Authors:  Andreas Kousios; Panayiotis Kouis; Andrie G Panayiotou
Journal:  Int J Nephrol       Date:  2016-03-02

9.  Variations in Circulating Active MMP-9 Levels During Renal Replacement Therapy.

Authors:  Elena Rodríguez-Sánchez; José Alberto Navarro-García; Jennifer Aceves-Ripoll; Judith Abarca-Zabalía; Andrea Susmozas-Sánchez; Teresa Bada-Bosch; Eduardo Hernández; Evangelina Mérida-Herrero; Amado Andrés; Manuel Praga; Mario Fernández-Ruiz; José María Aguado; Julián Segura; Luis Miguel Ruilope; Gema Ruiz-Hurtado
Journal:  Biomolecules       Date:  2020-03-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.